• 1
    Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55:434438.
  • 2
    Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001; 21:1726.
  • 3
    Luyckx FH, Lefebvre PJ, Scheen AJ. Non-alcoholic steatohepatitis: association with obesity and insulin resistance and influence of weight loss. Diabetes Metab 2000; 26:98106.
  • 4
    Knobler H, Schattner A, Zhornicki T, Malnick SDH, Keter D, Sokolovskaya N, Lurie Y, et al. Fatty liver—an additional and treatable feature of the insulin resistance syndrome. Q J Med 1999; 92:7379.
  • 5
    Day CP, James OFW. Steatohepatitis: a tale of two ‘hits’? Gastroenterology 1998; 114:842845.
  • 6
    Hill D, Shedlofsky S, McClain CJ, Diehl AM, Tsukamoto H. Cytokines and liver disease. In: RemickD, FriedlandJ, eds. Cytokines in health and disease. 2nd ed. New York: Marcel Dekker, 1997:401425.
  • 7
    Hill DB, Deaciuc IV, Nanji AA, McClain CJ. Mechanisms of hepatic injury in alcoholic liver disease. Clin Liver Dis 1998; 2:703721.
  • 8
    McClain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999; 19:205219.
  • 9
    Valenti L, Fracanzani AL, Dongiovanni P, Santorelli G, Branchi A, Taioli E, Fiorelli G, et al. Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122:274280.
  • 10
    Hill DB, Barve S, Joshi-Barve S, Glass J, Talwalker R, McClain CJ. Increased monocyte NFκB activation and tumor necrosis factor production in alcoholic hepatitis. J Lab Clin Med 2000; 135:387395.
  • 11
    Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Crose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor alpha in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48:148149.
  • 12
    Hill DB, Awad JA. Increased urinary F2-isoprostane excretion in alcoholic liver disease. Free Radic Biol Med 1999; 26:656660.
  • 13
    American Heart Association. Dietary guidelines for healthy American adults: a statement for physicians and health professionals by the Nutrition Committee, American Heart Association. Circulation 1998; 77:721A724A.
  • 14
    Hill DB, Deaciuc IV, McClain CJ. Hyperhyaluronanemia in alcoholic hepatitis is associated with increased levels of circulating soluble intercellular adhesion molecule-1. Alcohol Clin Exp Res 1998; 22:13241327.
  • 15
    Plevris JN, Haydon GH, Simpson KJ, Dawkes R, Ludlum CA, Harrison DJ, Hayes PC. Serum hyaluronan—a non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol 2000; 12:11211127.
  • 16
    Brunt EM, Janney CG, DiBisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94:24672474.
    Direct Link:
  • 17
    Pena LR, Hill DB, McClain CJ. Treatment with glutathione precursor decreases cytokine activity. J Parenter Enteral Nutr 1999; 23:16.
  • 18
    McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989; 9:349351.
  • 19
    Khoruts A, Stahnke L, McClain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991; 13:267276.
  • 20
    Hill DB, Marsano L, Cohen D, Allen J, Shedlofsky S, McClain CJ. Increased plasma interleukin-6 activity in alcoholic hepatitis. J Lab Clin Med 1992; 119:547552.
  • 21
    Hill DB, Marsano LS, McClain CJ. Increased plasma interleukin-8 concentrations in alcoholic hepatitis. Hepatology 1993; 18:576580.
  • 22
    Diehl AM. Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis. Alcohol Clin Exp Res 2001; 25(5 Suppl ISBRA):8S14S.
  • 23
    Honchel R, Ray MB, Marsano L, Cohen D, Lee E, Shedlofsky S, McClain CJ. Tumor necrosis factor in alcohol enhanced endotoxin liver injury. Alcohol Clin Exp Res 1992; 16:665669.
  • 24
    Nanji AA, Zhao S, Sadrzadeh SM, Waxman DJ. Use of reverse transcription-polymerase chain reaction to evaluate in vivo cytokine gene expression in rats fed ethanol for long periods. Hepatology 1994; 19:14831487.
  • 25
    Kamimura S, Tsukamoto H. Cytokine gene expression by Kupffer cells in experimental alcoholic liver disease. Hepatology 1995; 21:13041309.
  • 26
    Nanji AA, Zhao S, Sadrzadeh SMH, Sannenbert AJ, Tahan SR, Waxman DJ. Markedly enhanced cytochrome P450 2E1 induction and lipid peroxidation is associated with severe liver injury in fish oil-ethanol fed rats. Alcohol Mol Cell Biochem 1994; 140:8489.
  • 27
    Nanji AA, Miao L, Thomas P, Rahemtulla A, Khwaja S, Zhao S, Peters D, et al. Enhanced cyclooxygenase-2 gene expression in alcoholic liver disease in the rat. Gastroenterology 1997; 112:943951.
  • 28
    Adachi Y, Moore L, Bradford B, Gao W, Thurman R. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995; 108:218224.
  • 29
    Adachi Y, Bradford B, Gao W, Bojes H, Thurman R. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994; 20:453460.
  • 30
    Iimuro Y, Gallucci RM, Luster MI, Kono H, Thurman RG. Antibodies to tumor necrosis factor-α attenuate hepatic necrosis and inflammation caused by chronic exposure to ethanol in the rat. Hepatology 1997; 26:15301537.
  • 31
    Yin M, Wheeler MD, Kono H, Bradford BU, Gallucci RM, Luser MI, Thurman RG. Essential role of tumor necrosis factor α in alcohol-induced liver injury in mice. Gastroenterology 1999; 117:942952.
  • 32
    Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343:14671476.
  • 33
    Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94:25572562.
  • 34
    Eastin CE, McClain CJ, Lee EY, Bagby GJ, Chawla RK. Choline deficiency augments an antibody to tumor necrosis factor-a attenuates endotoxin-induced hepatic injury. Alcohol Clin Exp Res 1997; 21:10371047.
  • 35
    Chawla R, Watson W, Eastin C, Lee E, Schmidt J, McClain CJ. S-adenosylmethionine (AdoMet) deficiency and tumor necrosis factor (TNF) in lipopolysaccharide (LPS) induced hepatic injury. Am J Physiol 1998; 275:G125G129.
  • 36
    Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996; 111:16451653.
  • 37
    Grattagliano I, Vendemiale G, Caraceni P, Domenicali M, Nardo B, Cavallari A, Trevisani F, et al. Starvation impairs antioxidant defense in fatty livers of rats fed a choline-deficient diet. J Nutr 2000; 130:21312136.
  • 38
    Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99:14081413.
  • 39
    Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27:103107.
  • 40
    Angulo P, Lindor KD. Treatment of nonalcoholic fatty liver: present and emerging therapies. Semin Liver Dis 2001; 21:8188.
  • 41
    Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J, Rakela J, et al. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: a pilot study. Hepatology 1996; 23:14641467.
  • 42
    Abdelmalek MF, Angulo P, Jorgensen RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study. Am J Gastroenterol 2001; 96:27112717.
    Direct Link:
  • 43
    Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000; 6:9981003.
  • 44
    Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2002; 26:355356.
  • 45
    Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001; 96:519525.
    Direct Link:
  • 46
    Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: a pilot study. J Pediatr 2000; 136:734738.
  • 47
    Hill DB, Devalaraja R, Joshi-Barve S, Barve S, McClain CJ. Antioxidants attenuate nuclear factor-kappa B activation and tumor necrosis factor-alpha production in alcoholic hepatitis patient monocytes and rat Kupffer cells, in vitro. Clin Biochem 1999; 32:563570.
  • 48
    Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96:24612468.
  • 49
    Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288:20082014.